News

Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio has seen a steep increase in the number of women with cystic fibrosis (CF) choosing to become pregnant. “Due to the large pregnancy volume we…

Aceragen reached an agreement to acquire Arrevus, including its late-stage clinical program of ARV-1801 — now called ACG-721 — an experimental oral therapy for pulmonary exacerbations in cystic fibrosis (CF) patients. Aceragen is planning to launch a Phase 2/3 clinical trial in the second half of 2022…

The Cystic Fibrosis (CF) Foundation has invested $3 million in Armata Pharmaceuticals to support development of AP-PA02, a bacteriophage now being evaluated in a clinical trial for its ability to treat respiratory infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). “We are pleased by…

A platform to help people with cystic fibrosis (CF) better adhere to inhalation treatment, called the CFHealthHub, led to a substantial increase in the number taking medications as directed, according to a yearlong study. Although no benefits in lung function or pulmonary exacerbations were detected relative to usual care,…

Health Canada has granted priority review to an application that seeks to expand the approval of Trikafta to cover children with cystic fibrosis (CF) as young as 6 years. “We are pleased that [the application] has been accepted for Priority Review by Health Canada and we look forward…

Young children with cystic fibrosis (CF), relative to age-matched peers with disorders also affecting the lungs, show differences in bacterial communities and inflammation of the lower airways starting at around age 2, a study reported. A lesser variety of bacterial classes and more inflammation in the lower airways —…

Funding totaling £750,000 ($1,028,550) for a Strategic Research Centre (SRC) in the United Kingdom is expected to speed development of antibiotics to battle the lung infections that most cystic fibrosis (CF) patients experience. The four-year award from the Cystic Fibrosis Trust and the Cystic Fibrosis Foundation…

Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution, a new study reveals. “A long-standing lore in the cystic fibrosis field says that each patient’s infection tells a unique story, and that Pseudomonas evolves in unpredictable ways,” Jennifer Bomberger, PhD, said…

Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far been well-tolerated in a pilot clinical trial testing the investigational medication in adults with or without cystic fibrosis (CF). The ongoing trial involves patients with lung infections caused by…

Boehringer Ingelheim has taken legal steps giving it the lead role in further development of a long-lasting, inhalation gene therapy for cystic fibrosis (CF), called BI 3720931, that stems from a public-private research effort begun in 2018. The 2018 agreement brought together Boehringer, the U.K. Cystic Fibrosis…